score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	AR	Amplification				0.0	0.0		Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf	Putatively Actionable	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf						0				AR Amplification		SC_9029	SC_9029-Tumor	
Putatively Actionable			Clinical evidence	Copy Number	MYC	Amplification				0.0	0.0																Putatively Actionable	0.0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13.	https://doi.org/10.1007/s00401-011-0923-y	0				MYC Amplification		SC_9029	SC_9029-Tumor	
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.Q2637*	0.9535	43.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007													0	9.0	1.0	0.9999	ATM p.Q2637* (Nonsense)		SC_9029	SC_9029-Tumor	SC_9029-Normal
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.A430S	0.0546	1044.0	8.1e-05	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220						0	507.0	0.0434	1.0	AR p.A430S (Missense)		SC_9029	SC_9029-Tumor	SC_9029-Normal
Biologically Relevant				Somatic Variant	AURKA	Missense	p.R220G	0.5738	122.0	0.0	0.0																					0	68.0	0.4412	1.0	AURKA p.R220G (Missense)		SC_9029	SC_9029-Tumor	SC_9029-Normal
Biologically Relevant				Copy Number	RUNX1T1	Amplification				0.0	0.0																					0				RUNX1T1 Amplification		SC_9029	SC_9029-Tumor	
Biologically Relevant				Copy Number	ESRP1	Amplification				0.0	0.0																					0				ESRP1 Amplification		SC_9029	SC_9029-Tumor	
Biologically Relevant				Microsatellite Stability	Supporting variants		ESRP1 Amplification, MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: ESRP1 Amplification, MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		SC_9029		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.37																									0				COSMIC Signature (version 2) 1 (37%)		SC_9029		
Biologically Relevant				Mutational Signature	COSMIC Signature 15	version 2	0.216																									0				COSMIC Signature (version 2) 15 (22%)		SC_9029		
